Barclays
TEVA icon

Barclays’s Teva Pharmaceuticals TEVA Stock Holding History

Barclays’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-352,500
Closed -$7.12M – 5681
2025
Q3 		$7.12M Buy
+352,500
New +$6.19M ﹤0.01% 1938
2023
Q2 		– Sell
-78,900
Closed -$698K – 5066
2023
Q1 		$698K Buy
+78,900
New +$780K ﹤0.01% 3008
2021
Q4 		– Sell
-50,000
Closed -$487K – 4725
2021
Q3 		$487K Buy
+50,000
New +$468K ﹤0.01% 3213
2021
Q1 		– Sell
-317,000
Closed -$3.06M – 5177
2020
Q4 		$3.06M Hold
317,000
– – ﹤0.01% 1903
2020
Q3 		$2.86M Sell
317,000
-93,000
-23% -$984K ﹤0.01% 1803
2020
Q2 		$5.05M Sell
410,000
-962,100
-70% -$10.9M ﹤0.01% 1375
2020
Q1 		$12.3M Sell
1,372,100
-598,000
-30% -$6.13M 0.01% 874
2019
Q4 		$19.3M Buy
1,970,100
+783,900
+66% +$7M 0.01% 975
2019
Q3 		$8.16M Buy
1,186,200
+193,900
+20% +$1.49M 0.01% 1448
2019
Q2 		$9.16M Buy
992,300
+633,800
+177% +$7.64M 0.01% 1413
2019
Q1 		$5.62M Sell
358,500
-675,500
-65% -$11.9M ﹤0.01% 1574
2018
Q4 		$15.9M Buy
1,034,000
+79,700
+8% +$1.63M 0.01% 877
2018
Q3 		$20.6M Sell
954,300
-123,200
-11% -$2.86M 0.01% 835
2018
Q2 		$26.2M Sell
1,077,500
-296,100
-22% -$6.04M 0.02% 649
2018
Q1 		$23.5M Buy
1,373,600
+201,100
+17% +$3.93M 0.02% 774
2017
Q4 		$22.2M Sell
1,172,500
-278,700
-19% -$4.19M 0.02% 755
2017
Q3 		$25.5M Buy
1,451,200
+282,000
+24% +$6.35M 0.03% 565
2017
Q2 		$38.8M Buy
1,169,200
+796,100
+213% +$24.6M 0.04% 358
2017
Q1 		$12M Buy
373,100
+124,900
+50% +$4.26M 0.01% 780
2016
Q4 		$9M Buy
248,200
+88,200
+55% +$3.52M 0.01% 1007
2016
Q3 		$7.36M Sell
160,000
-1,038,900
-87% -$54.2M 0.01% 1045
2016
Q2 		$60.2M Buy
1,198,900
+934,000
+353% +$49.7M 0.08% 214
2016
Q1 		$14M Sell
264,900
-282,900
-52% -$16.6M 0.02% 616
2015
Q4 		$35.6M Buy
547,800
+121,300
+28% +$7.5M 0.04% 371
2015
Q3 		$23.9M Buy
426,500
+35,500
+9% +$2.3M 0.03% 521
2015
Q2 		$23.1M Buy
391,000
+170,400
+77% +$10.5M 0.03% 588
2015
Q1 		$13.7M Sell
220,600
-60,500
-22% -$3.52M 0.02% 900
2014
Q4 		$16M Sell
281,100
-57,000
-17% -$3.18M 0.02% 879
2014
Q3 		$17.9M Sell
338,100
-43,300
-11% -$2.29M 0.02% 785
2014
Q2 		$19.8M Sell
381,400
-160,600
-30% -$8.21M 0.02% 704
2014
Q1 		$28.2M Sell
542,000
-25,700
-5% -$1.19M 0.03% 518
2013
Q4 		$22.7M Sell
567,700
-207,700
-27% -$8.18M 0.02% 698
2013
Q3 		$28.7M Buy
775,400
+6,900
+0.9% +$269K 0.03% 499
2013
Q2 		$30.1M Buy
+768,500
New +$29.9M 0.04% 438

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Barclays's TEVA Position: Q1 2026 in Review

Barclays increased its Teva Pharmaceuticals (TEVA) stake by 0.36% in Q1 2026, buying an estimated $161K and bringing the position to 1,400,671 shares worth $42.2M. The position accounts for 0.01% of the portfolio, ranked #792.

Barclays first reported a position in TEVA in Q2 2013 and has held it in 52 quarters since. The position peaked at $160M in Q2 2016. 651 funds tracked by Wall St. Rank hold TEVA as of Q1 2026.

  • Barclays held 1,400,671 shares of Teva Pharmaceuticals worth $42.2M as of Q1 2026.
  • Barclays bought 5,000 Teva Pharmaceuticals shares in Q1 2026, an estimated $161K.
  • Teva Pharmaceuticals made up 0.01% of Barclays's portfolio in Q1 2026, its #792 holding.
  • Barclays first reported a position in Teva Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • Barclays's Teva Pharmaceuticals position peaked at $160M in Q2 2016.
  • 651 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.